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Reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (RIC-alloHSCT) is
associatedwith lower toxicity but higher rates of prolongedmixed chimerism thanmyeloablative conditioning.
Decreased pretransplantation host T cell numbers are associated with less graft rejection and early full donor
chimerism. To compensate for variability in pretransplantation host lymphocyte numbers and facilitate the
achievement of rapid full donor chimerism, we tested a strategy of targeted lymphocyte depletion (TLD) using
chemotherapy at conventional doses to provide cytoreduction and lymphocyte depletion before RIC-alloHSCT.
In our study, 111 patients with advanced hematologic malignancies received 1 to 3 cycles of conventional-dose
chemotherapy to reduce circulating lymphocytes to a predetermined level. Patients then underwent RIC-
alloHSCT from HLA-matched siblings. Patients received a median of 2 cycles of TLD chemotherapy, resulting
in a median 71% decline in CD4þ count. All patients engrafted; there were no late graft failures. By day þ14,
median CD3þ chimerism was 99% donor and was signiﬁcantly associated with lower post-TLD CD4þ counts
(P ¼ .012). One- and 5-year treatment-related mortality were 15% and 21%, respectively. At 1-year follow-up,
66% of patients had achieved complete remission (CR) of which 92% were not in CR at the time of trans-
plantation. Overall survival at 1 and 5 years post transplantation were 66% and 47%, respectively.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION
Reduced-intensity conditioning (RIC) regimens are asso-
ciated with decreased acute treatment-related toxicities,
thereby broadening the general application of allogeneic
hematopoietic stem cell transplantation (alloHSCT) [1-4].
Historically, RIC-alloHSCT has been associatedwith increased
relapse rates compared with myeloablative conditioning
regimens, particularly in patients with high-risk malignan-
cies [5,6]. Both murine models and clinical trials have
demonstrated that optimal graft-versus-tumor effects are
achieved in states of full donor T-lymphoid chimerism [7-9].
Therefore, higher relapse rates may not be explained com-
pletely by the decreased antitumor effects of the conditioning
regimen.
RIC often results in states of mixed donor and host
chimerism in the early transplantation period [10,11]. Factors
inﬂuencing engraftment include host immune status, histo-
compatibility, hematopoietic “space,” stem cell dose, and the
population of Tcells within the allograft [11-14]. Of these, host
immune status is the least studied and clinically understood.
Because of the signiﬁcant differences in the type and amount
of pretransplantation therapies of patients being considered
for RIC-alloHSCT, host immune status immediately beforedgments on page 1512.
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13.08.001transplantation is highly variable. To consistently achieve
a uniform result of early full donor chimerism, patients most
likely require different levels of conditioning intensity.
To address the issue of variability in host immune status,
we developed a novel treatment approach, referred to as
targeted lymphocyte depletion (TLD). The TLD approach is
based on a preclinical murine engraftment model, in which
the repetitive administration of moderate doses of disease-
speciﬁc chemotherapy resulted in a signiﬁcant depletion of
circulating T cells with minimal myelosuppression [15]. This
level of lymphocyte depletion, equivalent to that seen with
lethal doses of myeloablative conditioning, was sufﬁcient to
permit the engraftment of fully MHC-mismatched allografts.
Based on the these data, we hypothesized that: (1) circu-
lating lymphocytes are a surrogate marker of host immune
status; and (2) there exists a level of host T cells in humans
that is sufﬁciently low enough to consistently permit the
achievement of rapid and complete donor chimerism.
The TLD approach incorporates the standard clinical prac-
tice of administering “salvage” chemotherapy at conventional
doses before transplantation to reduce tumor burden. How-
ever, TLD utilizes agents that are both disease-speciﬁc and
lymphocyte depleting to reduce host T cells before RIC-
alloHSCT. The number of chemotherapy cycles administered
is based on reaching a target lymphocyte number; patients
with higher starting lymphocyte counts receive more
chemotherapy cycles. As such, TLD provides a personalized
approach to adjust for highly variable pretransplantation
patient lymphocyte numbers. We tested the TLD approach inTransplantation. Published by Elsevier Inc. All rights reserved.
Table 1
Patient Characteristics
Characteristic n
No. of patients 111
Age, median (range), yr. 50 (19 to 71)
Female/male 40/71
Histological Findings
Non-Hodgkins lymphoma 70
Indolent 17
Aggressive 53
Hodgkin lymphoma 12
Multiple myeloma 16
AML/MDS 4
CML 3
Other 6
No. of prior regimens, median (range) 3 (0 to 7)
Disease status at enrollment
Chemosensitive 58
Chemoresistant 51
CMV status of recipient
Negative 48
Positive 63
Minor ABO mismatch 76
Major ABO mismatch 22
Risk of relapse
Low 23
Medium 18
High 66
AML indicates acute myelogenous leukemia; MDS, myelodysplastic
syndrome; CML, chronic myelogenous leukemia; CMV, cytomegalovirus.
Data are presented as n unless otherwise indicated.
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going RIC-alloHSCT to determine effects on engraftment and
clinical outcomes.
METHODS
Patients
The TLD approach was evaluated in patients with advanced hematologic
malignancies participating in 4 sequential National Cancer Institute (NCI)
protocols NCT00019851, NCT00055744, NCT00077480, and NCT00074490
(http://clinicaltrials.gov/ct2/home). All 4 protocols were approved by the
NCI Institutional Review Board, and informed written consent was obtained
from each patient. Patients were eligible if they were between the ages of 18
and 75 years, had either primary treatment failure or relapse after salvage
therapy for a hematologic malignancy, and had an HLA-matched sibling.
Patients were not excluded based on disease chemotherapy-sensitivity,
which was deﬁned based on their response to their last pre-enrollment
chemotherapy regimen (chemosensitive was deﬁned as a complete res-
ponse [CR] or partial response [PR]; chemoresistant was deﬁned as stable
disease [SD] or progressive disease [PD]). There were no competing proto-
cols for this patient population during the time of enrollment at our insti-
tution. Engraftment was the primary objective of all the protocols that were
included in the analysis.
TLD Chemotherapy Regimen
TLD chemotherapy was given to patients with CD4þ counts greater than
200 cells/mL before RIC and consisted of the lymphocyte-depleting agent ﬂu-
darabine as either part of the dose adjusted (DA)-EPOCH-F regimen (etopo-
side, prednisone, vincristine, cyclophosphamide, and doxorubicin) [16,17] or
as part of the FLAG regimen (ﬂudarabine, cytarabine, G-CSF) [18], depending
onwhether thepatienthada lymphoidormyeloidmalignancy; themajorityof
the lymphoid malignancy patients had been included in our previously pub-
lished DA-EPOCH-FR study, which focused on pretransplantation response to
this novel chemotherapy regimen.
Chemotherapy cycles were repeated every 21 days with the goal of
achieving a CD4þ T cell count less than 200 cells/mL. If CD4þ < 200/mL was
achieved, no additional cycles were given (CD4þ count < 200 cells/mL was
chosen based on the AIDS literature that demonstrated that individuals with
CD4þ count < 200 cells/mL are at greatest risk of developing opportunistic
infections because cell-mediated immunity is markedly diminished).
Patients could receive a total of 3 cycles of TLD therapy, provided there was
adequate hematological recovery and no progression of disease. If enroll-
ment CD4þ count was < 200 cells/mL, no pretransplantation TLD chemo-
therapy was given.
Transplantation Regimen
All patients received an RIC regimen consisting of concurrent ﬂudar-
abine (30 mg/m2/day) and cyclophosphamide (1200 or 400 mg/m2/day;
protocol dependent) for 4 days (day -6 to day -3) followed by T cellereplete
peripheral blood stem cell allografts fromHLA-matched siblings. All patients
received a cyclosporine-based GVHD prophylaxis regimen.
Lymphocyte Monitoring by Flow Cytometry
Peripheral blood was collected before treatment and after each cycle of
TLD. Flow cytometry was performed using whole blood lysis in a Clinical
Laboratory Improvement Amendments (CLIA)ecertiﬁed laboratory (Science
Applications International Corporation, Frederick,MD). The absolutenumber
of CD3þ, CD4þ and CD8þ T, B, and NK cells per liter of blood was calculated
based upon the percentages of these cells in the lymphocyte gate, the
percentage of lymphocytes (deﬁned as CD45bright, CD14-, low side scatter)
and the white blood cell counts (Beckman Coulter Inc, Fullerton, CA). CD4þ
and CD8þ T cells were deﬁned as CD3þCD4þ or CD3þCD8þ, respectively.
B cells were deﬁned as CD3-CD19þ; NK cells were deﬁned as CD3-CD56þ.
Serum Interluekin-7 and Interleukin-15
nterleukin (IL)-7 and IL-15areTcell homeostatic cytokines thathavebeen
demonstrated to correlate with the degree of lymphocyte depletion [19]. In
a subset of patients, serum was obtained for IL-7 and IL-15 determination
before treatment and after hematopoietic recovery from each cycle of TLD
therapy, aswell as after theRIC regimen. Serumsampleswere frozenat80C
until analysis. Samples were thawed on ice and analyzed using a high-
sensitivity colorimetric ELISA (R&D Systems, Minneapolis, MN) according to
the manufacturer’s recommendations. A separate standard curve was
prepared on each plate using serial dilutions. Samples exceeding the highest
value on the standard curve were reanalyzed using serial dilutions. Plates
were read with a microplate reader (Molecular Devices, Sunnyvale, CA) and
analyzed using SOFTmax Pro 3.0 software. All samples were run in duplicate.
Intra-assay and inter-assay variability was less than 15%.Chimerism Evaluation
Hematopoietic chimerism was assessed using short-tandem-repeat
ampliﬁcation determined at baseline in the donor and patient. After trans-
plantation, patient peripheral blood was collected for analysis of lymphoid,
myeloid, and total chimerism on day þ14 post transplantation and every
2 weeks thereafter until donor chimerism was greater than 95%.
Statistical Methods
A variety of exploratory statistical methods were used to identify
potential associations between transplantation outcomes and demographic
or clinical parameters. A comparison of continuous parameters between 2
groups was done using a Wilcoxon rank-sum test, whereas comparisons of
continuous parameters between 3 or more unordered categories were done
using a Kruskal-Wallis test. Comparisons of dichotomous parameters
between 2 groups were done using a Fisher exact test, although compari-
sons of parameters with 2 or more categories and a second parameter with
more than 2 categories were performed using Mehta’s modiﬁcation to the
Fisher exact test [20]. The signiﬁcance of trends in ordered categorical
parameters across a dichotomous parameter were determined using an
exact Cochran-Armitage test [21].
The statistical signiﬁcance of the trends in an ordered categorical or
continuous parameter across an ordered categorical parameter were
determined by a Jonckheere-Terpstra test for trend [22]. Correlations were
determined by Spearman correlation analysis. Event-free survival (EFS) was
determined from the on-study date until the date of progression or death, or
until being censored at the date of last follow-up. Overall survival (OS) was
determined from the on-study date until death, or last follow-up. The
probability of OS or EFS as a function of time was determined by the Kaplan-
Meier method, with a log-rank test used to determine the statistical
signiﬁcance of the difference of a pair of Kaplan-Meier curves [23]. A Cox
proportional hazards model analysis was performed to determine the joint
association of factors initially found to have potential association with
outcome in the univariate analyses (those with unadjusted P < .10 from
a log-rank test) [24]. Cumulative incidence curves of treatment-related
mortality (TRM) and disease-related mortality were constructed using the
method of Gooley et al. [25].
All P values are 2-tailed and presented without adjustment for multiple
comparisons.
RESULTS
Patient Characteristics
One hundred and eleven patients were enrolled onto
protocol between August 1999 and May 2006 (Table 1). Of
Table 2
Lymphocyte Depletion after TLD Chemotherapy and after Reduced-Intensity
Conditioning
Enrollment Post TLD Post FC (Day 0)
CD3 þ cells/mL
Median (range)
673 (5 to 3953) 164 (1 to 1496) 4 (0 to 69)
CD4 þ cells/mL
Median (range)
286 (5 to 3888) 82 (0 to 508) 3 (0 to 65)
CD8 þ cells/mL
Median (range)
277 (1 to 1763) 52 (1 to 1195) 1 (0 to 44)
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61% had a high risk of relapse by Seattle criteria [26].
Lymphocyte Depletion and Chimerism
Ninety-four of 108 evaluable patients achieved CD4þ
< 200 cells/mL with TLD chemotherapy. The other 14 patients
either received the maximum 3 cycles without achieving
CD4þ < 200 cells/mL or had progressive disease. The median
CD3þ, CD4þ, and CD8þ counts at enrollment were 673 cells/
mL (range, 5 to 3953), 286 cells/mL (range, 5 to 3888), and 277
cells/mL (range, 1 to 1763), respectively (Table 2). After
a median number of 2 cycles of TLD chemotherapy, median
CD3þ, CD4þ, and CD8þ counts were: 164 cells/mL (range, 1 to
1496), 82 cells/mL (range, 0 to 508), and 52 cells/mL (range, 1
to 1195), reﬂecting a median relative decrease of 76%, 71%,
and 81%, respectively. Immediately before stem cell infusion
(day 0) median host CD3þ, CD4þ, and CD8þ counts were 4
cells/mL (range, 0 to 69), 3 cells/mL (range, 0 to 65), and 1 cell/
mL (range, 0 to 44), respectively.
One hundred and nine patients were evaluable for
engraftment, of which 100% engrafted; there were no late
graft failures. At post-transplantation day þ14, the median
CD3þ chimerism was 98% (range, 60% to 100%), CD14þ/15þ
chimerism was 100% (range, 20% to 100%) and whole blood
chimerism was 99% (range, 20% to 100%). Patients were able
to maintain full donor chimerism (deﬁned as  95% donor
chimerism) as evidenced by median 99% chimerism in CD3þ
and median 100% chimerism in CD14þ/15þ and whole blood
at day þ28 and whole blood at day þ100 (Table 3).
Full donor CD3þ chimerism at post-transplantation
day þ14 was associated with lower post-TLD CD4þ counts
(median, 78 cells/mL versus 128 cells/mL in patients with
versus without full donor chimerism; P ¼ .012) and day
0 (before allograft infusion) CD3þ, CD4þ, and CD8þ counts
(P < .0005). Full donor CD14þ/15þ chimerism at dayþ14 and
day þ28 was associated with lower day 0 CD3þ, CD4þ, CD8þ
counts (P < .05). Full donor whole blood chimerism at post-
transplantation days þ14, þ28, and þ100 were associated
with lower day 0 CD3þ, CD4þ, and CD8þ counts (P< .05). The
CD3þ and CD34þ dose contained in the allograft was asso-
ciated with day þ14 CD3þ chimerism (P ¼ .04) and with
day þ28 CD14þ/15þ chimerism (P ¼ .03), respectively.
IL-7 and IL-15 Determination
A subset of 31 patients had IL-7 and IL-15 samples
tested at baseline, after each sequential cycle of TLDTable 3
Early Post-Transplantation Myeloid, Lymphoid, and Whole Blood Chimerism
Day þ14
CD14þ/15þ, median (range) 100% (20% to 100%)
CD3þ, median (range) 98% (60% to 100%)
Whole blood, median (range) 99% (20% to 100%)chemotherapy and after completion of the conditioning
chemotherapy before allograft infusion. The median IL-7
level at baseline from 27 observations was 12.9 pg/mL
(range, 0.0 to 46.9). Median level of IL-7 after 1 to 3 cycles
of TLD was 21.3 pg/mL (range, .8 to 63.5). Post condi-
tioning, the median IL-7 level was 37.0 pg/mL (range, 13.3
to 79.2). The median IL-15 level of 26 evaluable patients at
baseline was 1.9 pg/mL (range, 0.1 to 13.6). Median IL-15
level after 1 to 3 cycles of TLD was 7.7 pg/mL (range, .8
to 48.0). Post conditioning, the median IL-15 level was
61.6 pg/mL (range, 22.3 to 205.3). Increases in IL-7 levels
were weakly associated with a decrease in CD3þ (r ¼ -.31;
P ¼ .13), CD4þ (r ¼ .32; P ¼ .12), and CD8þ (r ¼ .18;
P ¼ .36) counts, respectively. Increases in IL-15 levels were
weakly associated with decreases in CD3þ (r ¼ .33; P ¼
.11) and CD8þ (r ¼ .25; P ¼ .23) and moderately associ-
ated with a decrease in NK cell (r ¼ .64; P ¼ .0007)
counts.Acute and Chronic GVHD
The cumulative incidence of grades II to IV and grades III
to IV acute GVHD (aGVHD) was 46% and 23%, respectively.
The cumulative incidence of patients with chronic GVHD
(cGVHD) was 59% (25% limited, 75% extensive). Patients with
aGVHD II to IV had signiﬁcantly higher CD4þ count after TLD
(median, 110 cells/mL versus 77 cells/mL in patients with
versus without aGVHD; P ¼ .013). Patients with acute GVHD
III to IV had signiﬁcantly higher CD4þ and CD3þ counts at day
0 (P ¼ .03 and P ¼ .02, respectively).Response, Mortality and Survival
By day þ28 after transplantation, 38 patients (35%)
achieved (n ¼ 27) or maintained a CR (n ¼ 11) and 44 (40%)
achieved (n ¼ 21) or maintained (n ¼ 23) a PR. Twelve
additional CRs were observed at day þ100 without with-
drawal of immunosuppression or donor lymphocyte infu-
sion. Because many of the patients were enrolled on study
before positron emission tomography (PET) scan was
considered standard of care, the initial cohort of patients
did not routinely get PET scans for their restaging. In the
later cohorts, PET was used more frequently but not
uniformly to assess response for lymphoproliferative
diseases. EFS and OS at 1 year were 49% and 66% and were
31% and 47% at 5 years, respectively (Figure 1). One- and
5-year TRM were 15% and 21%, respectively. Seventy-three
patients were alive at their 1-year follow-up, of which 48
patients (66%) were in CR. Ninety-two percent of these
patients had not been in CR at the time of transplantation.
By univariate analysis, younger age of recipient and lack of
an ABO major mismatch were signiﬁcantly associated
(P < .05) with OS; number of prior therapies, disease status
at the time of transplantation, and relapse risk by Seattle
criteria were signiﬁcantly associated (P < .05) with both EFS
and OS. Positive cytomegalovirus serology was associated
with both lymphoid (P ¼ .022) and whole blood chimerism
(P ¼ .034) at day þ14.Day þ28 Day þ100
100% (40% to 100%) 100% (35% to 100%)
99% (70% to 100%) 100% (65% to 100%)
100% (10% to 100%) 100% (0 to 100%)
Figure 1. Event-free and overall survival for all patients enrolled in study.
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Pretransplantation chemotherapy has been shown to
facilitate engraftment by decreasing recipient immune
competence and weakening the host-versus-graft reaction
[27]. In a study by Childs et al., it was ﬁrst established that
control of malignant disease after nonmyeloablative condi-
tioning was dependent on engraftment of donor T lympho-
cytes and occurrence of graft-versus-tumor effects [28]. This
was corroborated by Keil et al., who demonstrated that
patients with less than 90% donor T cell chimerism on
day þ28 had signiﬁcantly higher risks of graft rejection and
disease relapse than those with greater than 90% T cell donor
chimerism [29].
The variability inherent in pretransplantation host im-
mune status is evident by the large range of circulating T cell
numbers in patients referred to our institution for trans-
plantation. By using TLD, wewere able to compensate for this
inconsistency while achieving levels of host T cell depletion
comparable to levels achieved with myeloablative condi-
tioning. Although RIC regimens are associated with fewer
toxicities and lower rates of early TRM, the risks of graft
rejection are higher because residual recipient immunity is
still present [30]. Whereas there is some evidence to suggest
that prolonged antigen presentation by donor cells in mixed
chimeras leads to enhanced graft-versus-tumor effect
[31,32], several studies have clearly shown an increased risk
of relapse in the setting of mixed chimerism [21,33]. Early
CD3þ complete donor chimerism has been demonstrated to
be more common in immunosuppressed hosts, and exposure
to chemotherapy immediately before transplantation has
been shown in several studies to correlate with better
outcomes [27,34]. Using the strategy of TLD before RIC-
alloHSCT, we conﬁrmed our hypothesis that the degree of
pretransplantation lymphocyte depletion is associated with
the establishment of early post-transplantation full donor
chimerism. In the current study, almost 100% of recipients
had full donor T cell chimerism by post-transplantation
day þ14, which was sustained at days þ28 and þ100.
Under normal T cell homeostasis, fewer cytokines are
available because of consumption by the endogenous
lymphocyte population. After lymphocyte depletion,
however, the consumptive cellular cytokine “sinks” are
removed and adoptively transferred T cells have greater
access to IL-7, IL-15, and IL-21 [35]. This is followed by
preferential homeostatic expansion of adoptively transferred
T cells. The TLD approach reduced circulating T cell numbers
by 70% to 80%, which correlated with a signiﬁcant increase in
both serum IL-7 and IL-15. This is in contrast to recentlypublished data by De Bock et al., who demonstrated that IL-7
and IL-15 levels did not increase after RIC-alloHSCT com-
pared with the increase they demonstrated in myeloablative
conditioining [36]. This corroborates the assertion that the
reductions in circulating Tcell numbers accomplished by TLD
may enhance total body T cell depletion over and abovewhat
is achieved by RIC alone.
In patients with high risk of relapse by the Seattle criteria
[26] and extensive amounts of prior chemotherapy, the long-
term EFS and OS data reported in the current study are
notable. It raises the possibility that by giving additional
doses of disease-speciﬁc chemotherapy to achieve lympho-
cyte depletion, we are also eradicating minimal residual
disease (MRD), which in multiple studies has been demon-
strated to lead to a more favorable outcome [37-39]. In
a prior paper that came out of our institution, the number of
cycles of EPOCH-F/R was signiﬁcantly associated with overall
response rate: 1 cycle, 17%; 2 cycles, 33%; 3 cycles, 84%;
P< .001 [16]. Therefore, it can be argued that patients should
be treated until best response. This would be worth pursuing
in future studies.
We conclude that TLD provides a personalized approach
to pretransplantation host immune status resulting in
absence of graft rejection and rapid and full donor chimerism
after RIC-alloHSCT. This approach results in long-term
survival in a high-risk population of patients with hemato-
logic malignancies undergoing RIC-alloHSCT. Although the
number of patients with myeloid malignancies was too small
to draw any generalizable conclusions, pretransplantation
MRD in this population is a subject of much current interest
and the strategy of lymphocyte-depleting disease targeted
chemotherapy before RIC-alloHSCT would be a strategy
worth exploring. Limitations of this investigation include the
variability inherent in the 4 protocols completed over a 10-
year time span and the diversity of disease histologies
included in the analysis. Future directions consist of
a prospective assessment looking at a more uniform group of
patients, such as those with lymphoproliferative disease, as
well as expanding this paradigm to populations more likely
to experience graft rejection, such as patients with unrelated
donors and in cord blood transplantation.
Reduced-intensity transplantation is commonly used for
patients with both myeloid and lymphoid malignancies who
are older or have comorbidities. We have previously reported
that pretransplantation disease-targeted chemotherapy
before RIC-alloHSCT can be well tolerated by this patient
population and results in the majority of patients entering
transplantation with less disease. In this current report, we
expand upon these results to demonstrate that pre-
transplantation disease-targeted chemotherapy also provides
signiﬁcant lymphocyte depletion, homeostatic cytokine
expansion, and early full donor chimerism, which has not
beenpreviously reportedwith reduced-intensityconditioning
alone. This approach avoids issues of mixed chimerism that
may lead to early withdrawal of immune suppression or DLI
that are necessitated by many RIC preparative regimens.ACKNOWLEDGMENTS
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